Focused on different pharmacological aspects of tumor responses to new antitumor drugs. Our specific expertise is concentrated on molecular and cellular biology, in vitro/vivo tests on our murine and human xenografts models:
More than 70 xenograft plus orthotopic and metastatic models are available for the evaluation of new compound efficacy.
All experimental activities are under quality control with GLP - like standard procedures

Drugs screening by tailoring the models to their mechanism of action. Evaluation of antitumor activity of selected agents/rational combinations, in human solid tumor models characterized in terms of expression of relevant targets.

Orthotopic & etastasis models:

Bio-imaging to monitor internal tumours & metastases.

• Evalution of tumours with Quantitative Bioluminescent Imaging:

A large panel of bioluminescent pre-clinical models which can be avaluated in real time using the optical molecular imaging system IVIS Spectrum from Caliper Life Sciences.

• Humanised Models: 

Human tumour epithelial cells transplanted with stromal cells

• Tumour micro-environment imaging:
  Dual bioluminescent/fluorescent biological reporters activated by different drugs or environmental stimuli

Anti-cancer drugs evalution Administration of therapeutic candidates by different routes (i.v., s.c.i.p., p.o. intramuscolar, intratracheal, slow release devices) with complex dosing (multiple daily administration) or in combination with standard of care.

• Standard immunochemistry methods to evaluate:
  • Proliferation, Apoptosis, Necrosis, Angiogenesis
  • Diagnostic/biomarker detection
  • ELISA analysis of serum and tissues for a comprehensive range of biological targets/marker